Clinical Trial Update: Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sorafenib tosylate in combination with Yttrium-90 glass microspheres for unresectable liver cancer (hepatocellular carcinoma).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib tosylate (sorafenib tosylate)
• Yttrium-90 glass microspheres (yttrium-90 glass microspheres)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-12-30